Letrozole and anastrozole in early breast cancer postmenopausal patients in oncology department at Suez Canal University Hospital

Manar Montasser, Ihab M.A. Hassanin, Soheir E. Abdelmohsen, Maha L. Zamzam


Background: There are limited data in the literature comparing the efficacy of aromatase inhibitors in postmenopausal hormonal receptor positive early breast cancer patients.
Aim of study: To compare the efficacy of letrozole and anastrozole in hormone-receptor positive postmenopausal breast cancer patients.
Methods: A retrospective study with a mean follow-up period of 64 months (about 5 years) for 74 files of early invasive postmenopausal breast cancer hormonal receptor positive patients; 39 received letrozole and 35 received anastrozole, considering TTP as primary end point, and OS as second end points.
Results: Letrozole is not superior to anastrozole during the first 55 months of treatment (80% PFS at 5th year), and 80% OS benefit at 6th year. Overweight patients had better (90% PFS at 5th year) than obese patients (60% PFS at 5th year).
Conclusion: Letrozole is not superior to anastrozole in efficacy in early invasive hormonal receptor positive breast cancer postmenopausal patients during the first 5 years of treatment; however, Letrozole 2nd line after tamoxifen is superior to anastrozole 2nd line after tamoxifen in treating obese patients with early invasive hormone receptor positive breast cancer.

Full Text:


DOI: https://doi.org/10.5430/jst.v9n1p12

Journal of Solid Tumors

ISSN 1925-4067(Print)   ISSN 1925-4075(Online)

Copyright © Sciedu Press

To make sure that you can receive messages from us, please add the 'Sciedupress.com' domain to your e-mail 'safe list'. If you do not receive e-mail in your 'inbox', check your 'bulk mail' or 'junk mail' folders.